Trial Profile

A Phase I Study Using Most Closely HLA-matched Cytomegalovirus-specific T Lymphocytes for the Treatment of Cytomegalovirus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-C)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytomegalovirus specific T cells ViraCyte (Primary)
Indications Cytomegalovirus infections
Focus Adverse reactions
Sponsors AlloVir; ViraCyte

Most Recent Events

10 Sep 2019 According to an AlloVir media release, results were published in the journal BLOOD ADVANCES.
10 Sep 2019 Results presented in an AlloVir media release.
11 Jul 2017 Results published in a ViraCyte media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com